- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Design
- Digital Marketing Rights
- DRM
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- Uncategorized
- USPTO
- Vietnam
- WIPO
Patents and Public Health
Introduction Patents and public health is the most relevant topic of discussion when the whole world is fighting against the global pandemic, Covid-19. It is no doubt that granting patent protection to a drug is important and serves many purposes, but can we put the lives of millions of people at stake in this time … Continue reading Patents and Public Health
Read more »The Development Of Human Rights Issues (Access To Medicines) In The Light Of Intellectual Property Rights
There is a constant conundrum between Intellectual Property and Human Rights in today’s day and age. There has been an emergence of International Human Rights obligations post World War II. A plethora of International Organizations like the WHO (public health), Universal Declaration of Human Rights 1948 (UDHR), International Covenant on Civil and Political Rights 1966 … Continue reading The Development Of Human Rights Issues (Access To Medicines) In The Light Of Intellectual Property Rights
Read more »Pharma Companies Extend Patent Life With Slight Modifications
Introduction The pharmaceutical industry is one of the most potential industry which has huge profit margins. Extensive growth and knowledge are required with frequent changes for better technology and results. Starting from early to the final stage there are gigantic chances of the product’s to face success or failure. Apart from these challenges, a large … Continue reading Pharma Companies Extend Patent Life With Slight Modifications
Read more »Unboxing The Confusion In Marks Of Pharmaceutical Products
It is not new that the Supreme Court had cautiously laid down the seven principles for determining confusion or deceptiveness in pharmaceutical products. The landmark case of Cadilla held that medicines are boon but if given wrongly it can have life-threatening impact. Thus, there need not be an iota of confusion in the mind of … Continue reading Unboxing The Confusion In Marks Of Pharmaceutical Products
Read more »Successful Completion of International Patent Drafting Competition 2017
IIPRD, along with Khurana & Khurana, Advocates and IP Attorneys (K&K) and its eminent foreign associates, conducted Third edition of International Patent Drafting Competition (IPDC). IPDC was designed with an objective to test acumen and skill set of various practitioners pertaining to patent drafting that forms a critical part in patent lifecycle. IPDC aims to … Continue reading Successful Completion of International Patent Drafting Competition 2017
Read more »Injunction against Cipla COPD Drug ‘INDAFLO’ Upheld: Delhi High Court
April 14, 2017 - 6:32 am
Categories:
India
Intellectual Property
Interim Injunction
News & Updates
Patents
pharma
0 Comments
Reportedly, on an appeal filed by Cipla pertaining to COPD drug INDAFLO, the Delhi High court division bench maintained the interim injunction imposed by single judge against Cipla. As per the order, Cipla has now been restrained from, inter alia, using, manufacturing, importing, selling any pharmaceutical products etc. containing ‘INDACATEROL‘ or ‘INDACATEROL Maleate‘, alone or … Continue reading Injunction against Cipla COPD Drug ‘INDAFLO’ Upheld: Delhi High Court
Read more »Analysis of the rejection of Lumacaftor (Polymorph) patent application in India
We have been receiving requests from our Pharma clients/readers of the blog for the analysis of the decision/ facts that led to rejection of Lumacaftor (Polymorph) patent application in India since last year. Here is our take: Details of the Patent Application and important dates: Patent application number in India 2056/KOLNP/2010 Title of the invention … Continue reading Analysis of the rejection of Lumacaftor (Polymorph) patent application in India
Read more »U.S. District Court Confirms Validity of Patent For UCB Pharma’s Vimpat®
August 17, 2016 - 5:19 am
Categories:
News & Updates
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
USPTO
0 Comments
UCB Pharma, a Belgian pharmaceutical company, announced on 14th August 2016 that the U.S. District Court for the District of Delaware confirmed the validity of its U.S. reissued patent RE38551 related to anti-epileptic drug Vimpat® (lacosamide). The patent challenge was brought by generic drug makers who had questioned the validity of the UCB’s patent which … Continue reading U.S. District Court Confirms Validity of Patent For UCB Pharma’s Vimpat®
Read more »India’s First IP Crime Unit Launched in Telangana State
August 16, 2016 - 4:42 am
Categories:
Copyright
India
News & Updates
Patents
pharma
Trademark
0 Comments
Piracy is one of the major evil Indian IP industry is facing for decades and the same is growing day by day rooting into the system causing irreparable loss to the economic reputation of the country. As per the report by Ernst & Young, Indian films industry has sustained loss of around USD 959 (Rs. … Continue reading India’s First IP Crime Unit Launched in Telangana State
Read more »Combating Opioid Misuse – COMBAT (Curb Opioid Misuse By Advancing Technology Act of 2016)
The Congress recently introduced a bill on the COMBAT Act (Curb Opioid Misuse By Advancing Technology Act of 2016) to incentivize the development of abuse-deterrent opioids by amending the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for certain drug products developed or labeled so as to reduce drug abuse, and for … Continue reading Combating Opioid Misuse – COMBAT (Curb Opioid Misuse By Advancing Technology Act of 2016)
Read more »